胰岛素
胰高血糖素
肠促胰岛素
艾塞那肽
利拉鲁肽
胰高血糖素样肽-2
药理学
2型糖尿病
作者
Nurunnabi,Seung Ah Lee,Vishnu Revuri,Yong Hwa Hwang,Sung Hun Kang,Minhyung Lee,Sungpil Cho,Kwang Jae Cho,Youngro Byun,You Han Bae,Dong Yun Lee,Yong-kyu Lee
标识
DOI:10.1016/j.jconrel.2017.08.035
摘要
The number of people suffering from insulin-independent type 2 diabetes mellitus (T2DM) is ever increasing on a yearly basis. Current anti-diabetic medications often result in adverse weight gain and hypoglycemic episodes. Hypoglycemia can be avoided with glucagon-like peptide (GLP)-1 receptor agonists, which are expensive and require daily injections that may result immune activation. This study demonstrates the use of non-viral vector based oral delivery of GLP-1 gene through enterohepatic recycling pathways of bile acids. Oral administration of the plasmid DNA (pDNA) encoding GLP-1 decreased diabetic glucose levels to the normoglycemic range with significant weight reduction in a high-fat diet (HFD) induced diabetic mouse model and a genetically engineered T2DM rat model. This novel oral GLP1 delivery system is an attractive alternative to treat late-stage T2DM conditions that require repeated insulin injection and can potentially minimize the occurrence of hypoglycemic anomalies.
科研通智能强力驱动
Strongly Powered by AbleSci AI